[Special Stock] SK Biopharm Surges Over 10% with Record High Performance Since Establishment

[Asia Economy Reporter Myunghwan Lee] SK Biopharm is soaring more than 10% during trading on the 8th following news that it recorded its highest-ever performance since its establishment.

As of 1:37 PM on the same day, SK Biopharm is trading at 87,800 KRW, up 11.42% (9,000 KRW) from the previous trading day.

SK Biopharm announced this morning that it achieved sales of 418.6 billion KRW and an operating profit of 95.3 billion KRW last year based on consolidated financial statements. The sales figure represents a 1,510.24% increase compared to the previous year, marking the highest performance since the company's founding. Net profit turned positive at 83.5 billion KRW.

The company explained that the innovative epilepsy drug 'Cenobamate' led the overall growth. Cenobamate expanded its business by entering major markets including the United States, Europe, Japan, and China last year. The increase in Cenobamate's sales in the U.S. and milestone payments received following European approval significantly contributed to the improved performance.

An SK Biopharm official stated, "While continuing qualitative growth with an upward trend in major markets such as the U.S. and Europe, we plan to actively pursue technology exports to various regions including South America, thereby promoting quantitative growth as well."

This content was produced with the assistance of AI translation services.